Metastatic carcinoid tumor with severe double valve disease at diagnosis: Case report and review of literature

  • Edna Juarez Department of Internal Medicine, Texas Tech University Health Sciences Center, Lubbock, TX
  • Avinash Adiga Department of Internal Medicine, Texas Tech University Health Sciences Center, Lubbock, TX
  • Paloma Sanchez Department of Internal Medicine, Texas Tech University Health Sciences Center, Lubbock, TX
  • Hilal Fanasch Department of Internal Medicine, Texas Tech University Health Sciences Center, Lubbock, TX
Keywords: carcinoid heart disease, carcinoid tumor, carcinoid syndrome

Abstract

A 27-year-old woman with a history of anxiety presented with three months of diarrhea. On
physical examination, she had a grade 3/6 systolic heart murmur at the lower left sternal border
which increased with inspiration, a grade 2/6 decrescendo diastolic murmur at the left sternal
border, and lower extremity edema. Stool studies were negative. The abdominal ultrasound
demonstrated multiple complex liver cysts. Transthoracic echocardiogram reported tricuspid
valvular thickening with stenosis and regurgitation, severe pulmonary stenosis, and mild aortic
regurgitation with valvular thickening. 5-hydroxyindole acetic acid and chromogranin A levels
were elevated. The patient’s symptoms improved after octreotide therapy, and she underwent
tricuspid and pulmonary valve replacement.
The incidence of carcinoid tumors is 1.2 to 2.1 per 100,000 people in the general population.
Carcinoid heart disease occurs in one-half to two-thirds of patients with carcinoid syndrome
and is associated with poorer clinical outcomes. Left side cardiac involvement occurs in less
than 10% of patients. The presence of both left and right sided valvular disease in the context
of gastrointestinal carcinoid is associated with severe and poorly controlled disease. Up to
4% of these cases have metastatic disease on the valves, and 3.8% have direct myocardial
involvement.

References

Papaxoinis G, Syrigos K, Saif MW. New concepts in the

treatment strategy of neuroendocrine tumors: The role of

biotherapy. Discov Med 2016; 21(117): 381–9.

Kunz PL. Carcinoids and neuroendocrine tumors: Building

on success. J Clin Oncol 2015; 1; 33(16):1855–63.

Yao JC, Hassan M, Phan A, Dagohoy C, Leary C, Mares

JE, Abdalla EK, Fleming JB, Vauthey JN, Rashid A, Evans

DB. One hundred years after “carcinoid”: Epidemiology

of and prognostic factors for neuroendocrine tumors

in 35,825 cases in the United States. J Clin Oncol 2008;

(18):3063–3072.

Mocellin S, Nitti D. Gastrointestinal carcinoid: Epidemiological

and survival evidence from a large population-based

study (n = 25 531). Ann Oncol 2013; 24(12):3040–4.

Öberg K. Neuroendocrine gastro-enteropancreatic tumors –

from eminence based to evidence-based medicine – A Scandinavian

view. Scand J Gastroenterol 2015; 50(6): 727–39.

Kulke MH, Siu LL, Tepper JE, Fisher G, Jaffe D, Haller DG,

Benedetti JK, Bergsland EK, Hobday TJ, Van Cutsem E,

Pinkpank J, Öberg K, Cohen SJ, Posner MC, Yao JC. Future

directions in the treatment of neuroendocrine tumors: Consensus

report of the National Cancer Institute Neuroendocrine

Tumor clinical trials planning meeting. J Clin Oncol

; 29(7): 934–43.

Klöppel G, Perren A, Heitz PU. The gastroenteropancreatic

neuroendocrine cell system and its tumors: The WHO classification.

Ann N Y Acad Sci. 1014: 13–27, 2004.

Modlin IM, Sandor A. An analysis of 8305 cases of carcinoid

tumors. Cancer 1997;79(4): 813–29.

Melmon KL, Sjoerdsma A, Oates JA, Laster L. Treatment of

malabsorption and diarrhea of the carcinoid syndrome with

methysergide. Gastroenterol 1965; 48: 18–24.

Melmon KL. Vasoactive substances in the pathogenesis of

migraine headache, carcinoid syndrome and other diseases.

Headache 1965; 5(3): 87–8.

Engelman K, Lovenberg W, Sjoerdsma A. Inhibition of serotonin

synthesis by para-chlorophenylalanine in patients with

carcinoid syndrome. N Engl J Med 1967; 277(21): 1103–8.

Anderson AS, Krauss D, Lang R. Cardiovascular complications

of malignant carcinoid disease. Am Heart J 1977;

(4):693–702.

Bernheim AM, Conolly HM, Hobday TJ, Pellikka PA. Carcinoid

heart disease. Prog Cardiovasc Dis 2007; 49(6): 439-51.

Palaniswamy C, Frishman WH, Anorow WS. Carcinoid

heart disease. Cardiol Rev 2012; 20(4): 167–76.

Manoly I, McAnelly SL, Sriskandarajah S, McLaughlin KE.

Prognosis of patients with carcinoid disease after valvular surgery.

Interact Cardiovasc Thorac Surg 2014; 19(2): 302–5.

Edwards NC, Yuan M, Nolan O, Pawade TA, Oleofse T,

Singh H, Mehrzad H, Zia Z, Geh JI, Palmer DH, May CJ,

Ayuk J, Shah T, Rooney SJ, Steeds RP. Effect of valvular

surgery in carcinoid heart disease: An observational cohort

study. J Clin Endocrinol Metab 2016; 101(1): 183–90.

Published
2017-10-16
How to Cite
Juarez, E., Adiga, A., Sanchez, P., & Fanasch, H. (2017). Metastatic carcinoid tumor with severe double valve disease at diagnosis: Case report and review of literature. The Southwest Respiratory and Critical Care Chronicles, 5(21), 26-31. https://doi.org/10.12746/swrccc.v5i21.416